Unaudited Financial Results for the Quarter and Half year ended 30.09.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ANG Lifesciences India posted standalone Q2 FY26 revenue of about ₹2,453 lakhs, down roughly 24% from around ₹3,216 lakhs in Q2 FY25, marking a sharp year-on-year decline. The company reported a Q2 FY26 standalone loss of approximately ₹103 lakhs, wider than the ~₹67 lakh loss in Q2 FY25. For H1 FY26, revenue was broadly flat at ~₹5,088 lakhs (vs ~₹5,006 lakhs in H1 FY25), while the half-year loss narrowed to about ₹164 lakhs from ~₹442 lakhs previously. Statutory auditor Khurana Sharma & Co. issued an unmodified review opinion on both standalone and consolidated results. The Board also approved the appointment of M/s Shreya Sahu & Associates as cost auditor for FY25-26, and cash and equivalents declined from ₹24.30 lakhs to ₹6.82 lakhs over the half-year, signalling weak liquidity.
The steep quarterly revenue drop, persistent losses, and shrinking cash buffer point to ongoing financial stress that could weigh on the stock in the near term, although the narrower half-year loss offers a small positive signal. Shareholders should watch for further deterioration in revenue and cash generation.